Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study

Inclusion: * Male or female Veterans aged 25- 65 who have serum PFAS \>20 ng/ml exceeding National Academy of Science guidance. * Written informed consent will be obtained. * Outpatient. * Agreeable to participate in sharable data and biorepository. Exclusion: * Under the age of 25 years * Unable or unwilling to sign the informed consent statement and HIPAA Authorization form * Females who are pregnant (confirmed by urine pregnancy test), nursing or planned pregnancy within study period. * Patients with hypertriglyceridemia, vitamin deficient patients, hyperthyroidism and diabetic, pancreatitis and intestinal and bowel obstruction * Be receiving any investigational drug other than Colesevelam or participating in any other investigational study. * Significant medical illnesses that may limit the subject's ability to complete follow-up visits, in the opinion of the investigator. * Be receiving any non-standard immunosuppression protocol or other non-standard treatment that could affect interpretation of the study results. * Those with significant cardiovascular disease including treatment with inotropes. * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. * Active substance abuse if this, in the opinion of the investigator, will interfere with the subject's ability to adhere to the study protocol.